Categories Earnings, Health Care
Zynerba Pharmaceuticals stock soars on receiving US patent for its CBD gel to treat Fragile X syndrome
Cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE) received US patent named “Treatment of Fragile X Syndrome with Cannabidiol”. Shares of Zynerba soared 15% in the pre-market trading hours on Tuesday.
This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the company’s cannabidiol (CBD) product candidate, ZYN002 Transdermal CBD gel.
Zynbera is enrolling FXS patients in the US, Australia and New Zealand for CONNECT-FX study that will evaluate its CBD gel ZYN002. The Devon, Philadelphia-based pharma company expects to report top-line data in the second half of 2019.
Fragile X syndrome (FXS) is a genetic disorder that affects both males and females. As of now, there is no cure for FXS, which causes intellectual disability, behavioral and learning challenges, and developmental delays in children.
About 71,000 US patients are believed to have FXS, based on FXS prevalence estimates of approximately 1 in 3,600 to 4,000 in males and of approximately 1 in 4,000 to 6,000 in females.
The company also expects to announce top-line data results from the other three childhood neuropsychiatric studies in the next two years (one in the third quarter of 2019 and two in the first half of 2020).
Zynerba stock, which ended Monday’s trading session down 1.56% at $5.04, had jumped 70% since the beginning of 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Docusign (DOCU) Earnings: 4Q25 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported total revenue of $776.3 million for the fourth quarter of 2025, up 9% year-over-year. Net income was $83.5 million, or $0.39 per share, compared to
DG Q4 Call Highlights: Consumer Shifts, Inventory Wins, and Rural Delivery Boom!
Dollar General Corp., a retailer that operates discount stores, in its Q4 earnings call discussed Dollar General's financial strategy to reach 6-7% operating margins by 2028 through shrink reduction, inventory
ULTA Earnings: Highlights of Ulta Beauty’s Q4 2024 results
Ulta Beauty, Inc. (NASDAQ: ULTA), a leading retailer of cosmetics and personal care products, on Thursday reported a decrease in net sales for the fourth quarter of 2024. Fourth-quarter net